SAN FRANCISCO, Nov. 21, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced its plans to attend the Piper Jaffray 28th Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY on November 29-30, 2016.
Matthew R. Patterson, President and Chief Executive Officer, will participate on a gene therapy panel on November 30, 2016 from 10:00 a.m. to 10:55 a.m. EST.
About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases. We have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.
For more information regarding Audentes, please visit www.audentestx.com.
Thomas Soloway, CFO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-attend-piper-jaffray-28th-annual-healthcare-conference-300366116.html
SOURCE Audentes Therapeutics, Inc.